+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiviral Therapeutics Market by Disease Type (Covid-19, Cytomegalovirus, Hepatitis C), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Interferons), Route Of Administration, Distribution Channel, Therapy Type - Global Forecast 2025-2030- Product Image
Antiviral Therapeutics Market by Disease Type (Covid-19, Cytomegalovirus, Hepatitis C), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Interferons), Route Of Administration, Distribution Channel, Therapy Type - Global Forecast 2025-2030- Product Image
Sale

Antiviral Therapeutics Market by Disease Type (Covid-19, Cytomegalovirus, Hepatitis C), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Interferons), Route Of Administration, Distribution Channel, Therapy Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5264367
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Antiviral therapeutics play a vital role within modern healthcare, enabling clinicians and organizations to address a diverse array of viral infections while bolstering global response capabilities against future threats. Dynamic advances in drug development, shifts in policy, and new supply chain realities are together shaping the strategic landscape for decision-makers finding opportunities in this expanding market.

Market Snapshot: Antiviral Therapeutics Market

The Antiviral Therapeutics Market grew from USD 82.01 billion in 2024 to USD 88.89 billion in 2025. It is expected to continue growing at a CAGR of 8.24%, reaching USD 131.94 billion by 2030. Sustained growth in this sector is propelled by evolving viral threats, rapid therapeutic innovation, intensified research and development activity, and an increased focus on resilient supply chains. Global health concerns and persistent viral outbreaks are compelling government agencies, pharmaceutical enterprises, and healthcare systems to expand investment in antiviral solutions and related infrastructure.

Scope & Segmentation

  • Disease Types: COVID-19, Cytomegalovirus, Hepatitis C, Herpes, HIV, Influenza, Respiratory Syncytial Virus
  • Drug Classes: Fusion Inhibitors, Integrase Inhibitors, Interferons, Monoclonal Antibodies, Neuraminidase Inhibitors, NNRTIs, NRTIs, Polymerase Inhibitors, Protease Inhibitors
  • Routes of Administration: Inhalation, Injectable, Oral, Topical
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Specialty Clinics
  • Therapy Types: Prophylaxis, Treatment
  • Regional Markets: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Leading Companies: Gilead Sciences, AbbVie, F. Hoffmann-La Roche, Merck & Co., Pfizer, Johnson & Johnson, GlaxoSmithKline, Bristol-Myers Squibb, Novartis, AstraZeneca

Key Takeaways

  • Continued innovation is fueling the evolution of platform technologies, including mRNA applications, gene editing, and monoclonal antibody engineering within the antiviral therapeutics sector.
  • Strategic alliances, licensing deals, and targeted acquisitions between incumbents and emerging biotech firms are shaping a competitive ecosystem that supports both novel and established antiviral modalities.
  • Adoption of flexible regulatory pathways by agencies worldwide is accelerating time-to-market for critical therapies, allowing for adaptive clinical designs informed by real-world data.
  • Expansion in regional manufacturing and contract development partnerships is strengthening supply chain resilience, helping manufacturers mitigate risks related to geopolitical factors or unexpected disruptions.
  • Segment analysis reveals that disease diversity and varied drug mechanisms prompt investment in both prevention and treatment, with innovation focused on unmet clinical needs and improved patient outcomes.

Assessing Tariff Impact on Antiviral Supply Chains

Anticipated tariff adjustments in the United States for 2025 are placing cost pressures on the antiviral therapeutics supply chain. Key impacts include potential increases in raw material and production costs—driven mainly by reliance on internationally sourced active ingredients—and changes in supplier and manufacturing strategies. In response, organizations are investigating stockpiling of critical components, deepening regional partnerships, and seeking policy exemptions to moderate financial strain and ensure timely, uninterrupted distribution of antiviral agents across care settings.

Methodology & Data Sources

This analysis is grounded in a dual-method approach, leveraging primary interviews with industry stakeholders and a comprehensive review of regulatory documents, scientific literature, and patent filings. Findings were validated through triangulation and peer review, ensuring robust, actionable insights for strategic planning and investment.

Why This Report Matters

  • Informs strategic investment decisions by delivering clear segmentation, technology trends, and regional growth opportunities across the antiviral therapeutics sector.
  • Supports proactive supply chain and policy planning by illuminating the impacts of evolving trade, reimbursement, and regulatory dynamics.

Conclusion

Antiviral therapeutics are undergoing rapid transformation through scientific innovation, resilient supply strategies, and collaborative frameworks. This market research provides stakeholders the clarity and strategic guidance needed to navigate an increasingly complex and vital sector of global health.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid advancement of mRNA-based antiviral therapeutics targeting emerging viral strains
5.2. Integration of artificial intelligence in antiviral drug candidate screening and optimization
5.3. Growing adoption of combination antibody and small molecule therapies for viral infection management
5.4. Emergence of long acting injectable antivirals for sustained suppression of chronic viral diseases
5.5. Development of broad-spectrum host-directed antivirals to reduce resistance development
5.6. Expansion of inhalable nanoparticle formulation to improve targeted antiviral lung delivery
5.7. Personalized antiviral regimens guided by viral genotyping and resistance profiling in clinics
5.8. CRISPR-Cas based gene editing approaches under clinical evaluation for targeted viral genome disruption
5.9. Real world evidence integration from electronic health records to monitor antiviral safety and efficacy trends
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antiviral Therapeutics Market, by Disease Type
8.1. Introduction
8.2. COVID-19
8.3. Cytomegalovirus
8.4. Hepatitis C
8.5. Herpes
8.6. Hiv
8.7. Influenza
8.8. Respiratory Syncytial Virus
9. Antiviral Therapeutics Market, by Drug Class
9.1. Introduction
9.2. Fusion Inhibitors
9.3. Integrase Inhibitors
9.4. Interferons
9.5. Monoclonal Antibodies
9.6. Neuraminidase Inhibitors
9.7. Nnrtis
9.8. Nrtis
9.9. Polymerase Inhibitors
9.10. Protease Inhibitors
10. Antiviral Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Inhalation
10.3. Injectable
10.4. Oral
10.5. Topical
11. Antiviral Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.5. Specialty Clinics
12. Antiviral Therapeutics Market, by Therapy Type
12.1. Introduction
12.2. Prophylaxis
12.3. Treatment
13. Americas Antiviral Therapeutics Market
13.1. Introduction
13.2. Canada
13.3. Mexico
13.4. United States
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Antiviral Therapeutics Market
14.1. Introduction
14.2. South Africa
14.3. Germany
14.4. Switzerland
14.5. Israel
14.6. Qatar
14.7. France
14.8. Nigeria
14.9. Poland
14.10. Sweden
14.11. Saudi Arabia
14.12. Norway
14.13. Egypt
14.14. Italy
14.15. Russia
14.16. United Kingdom
14.17. Turkey
14.18. Netherlands
14.19. Finland
14.20. United Arab Emirates
14.21. Denmark
14.22. Spain
15. Asia-Pacific Antiviral Therapeutics Market
15.1. Introduction
15.2. Indonesia
15.3. Thailand
15.4. Malaysia
15.5. Singapore
15.6. India
15.7. China
15.8. Australia
15.9. Philippines
15.10. Japan
15.11. Vietnam
15.12. Taiwan
15.13. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Gilead Sciences, Inc.
16.3.2. AbbVie Inc.
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.4. Merck & Co., Inc.
16.3.5. Pfizer Inc.
16.3.6. Johnson & Johnson
16.3.7. GlaxoSmithKline plc
16.3.8. Bristol-Myers Squibb Company
16.3.9. Novartis AG
16.3.10. AstraZeneca PLC
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTIVIRAL THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ANTIVIRAL THERAPEUTICS MARKET: RESEARCHAI
FIGURE 26. ANTIVIRAL THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 27. ANTIVIRAL THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 28. ANTIVIRAL THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTIVIRAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 84. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 85. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 92. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 93. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 94. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 95. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 96. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 97. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 148. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 150. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 151. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 156. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 157. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 158. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 159. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 167. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 168. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 169. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 176. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 177. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 178. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 179. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 180. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 181. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 186. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 187. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 188. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 189. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 190. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 191. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 196. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 197. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 198. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 199. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 206. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 207. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 208. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 209. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 210. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 211. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 216. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 217. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 218. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 219. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 220. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 221. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 226. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 227. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 228. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 229. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 230. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 231. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 236. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 246. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 247. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 248. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 249. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 250. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 251. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 256. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 257. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 258. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 259. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 260. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 261. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 262. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 263. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 266. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 267. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 268. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 269. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 270. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 271. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 276. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 297. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 298. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 299. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 300. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 301. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 306. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 307. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 308. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 309. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 310. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 311. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 313. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 316. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 317. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 318. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 319. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 320. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 321. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 322. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 323. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 324. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 325. FINLAND ANTIVIRAL THERAPEUTICS M

Samples

Loading
LOADING...

Companies Mentioned

  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Novartis AG
  • AstraZeneca PLC

Table Information

Report AttributeDetails
No. of Pages191
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 88.89 Billion
Forecasted Market Value ( USD ) by 2030 $ 131.94 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Antiviral Drugs Market by Indication (Hepatitis B, Hepatitis C, Herpes Simplex), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Non Nucleoside Reverse Transcriptase Inhibitors), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Antiviral Drugs Market by Indication (Hepatitis B, Hepatitis C, Herpes Simplex), Drug Class (Fusion Inhibitors, Integrase Inhibitors, Non Nucleoside Reverse Transcriptase Inhibitors), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Hepatitis Therapeutics Market by Therapeutic Class (Combination Therapies, Direct Acting Antivirals, Interferons), Genotype (Genotype 1, Genotype 2, Genotype 3), Route Of Administration, Distribution Channel, Stage Of Disease - Global Forecast 2025-2030 - Product Image

Hepatitis Therapeutics Market by Therapeutic Class (Combination Therapies, Direct Acting Antivirals, Interferons), Genotype (Genotype 1, Genotype 2, Genotype 3), Route Of Administration, Distribution Channel, Stage Of Disease - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Antiviral Combination Therapy Market Report 2025 - Product Image

Antiviral Combination Therapy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Specific Antiviral Drugs For COVID 19 Global Market Report 2025 - Product Image

Specific Antiviral Drugs For COVID 19 Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Oral Antivirals - Global Strategic Business Report - Product Image

Oral Antivirals - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.